Skip to content
Health News

Cancer drugs account for 27% of all new drug approvals in the U.S., says Tufts

By health | September 4, 2019
0 Comment

Cancer drugs currently account for 27% of all new drug approvals in the U.S. since 2010, a dramatic increase from the 4% share of the 1980s, a newly completed analysis from the Tufts Center for the Study of Drug Development shows.

From 1980 through 2018, the Food and Drug Administration approved a total of 126 cancer drugs to treat solid and hematologic tumors.

Joseph A. DiMasi, research associate professor and director of economic analysis at Tufts CSDD, said the surge in new oncology products is due to new approaches to development — efforts which have paid off in the form of more effective treatment options.

WHAT’S THE IMPACT

Pressure for even more oncology drugs is likely to continue, the analysis showed, given that there are still many cancers that are inadequately treated, or untreatable altogether.

Developers will be challenged to control development costs, especially those linked to recruiting enough patients for clinical trials involving rate cancers. There will also be pressure from payers to control drug prices and contain pharmaceutical spending.

The analysis also found that clinical development time for cancer drug approvals from 1999 to 2018 was 9% longer compared to non-cancer drugs.

Regulatory approval phase time for cancer approvals during that time period was 48% shorter on average compared to non-cancer approvals, while total clinical development and approval phase times was 17% longer on average for hematologic drugs (8.8 years) compared to drugs for solid tumors (7.5 years).

Meanwhile, substantially higher percentages of new cancer drug approvals received priority ratings from the FDA and had orphan drug status, compared to new non-cancer drug approvals.

See also  8 ways walking in the woods can make you happier

THE LARGER TREND

Health systems, including inpatient and non-acute environments, can expect a 4.57% increase in pharmaceutical spend for 2020. Vizient, which revealed that finding in its recent 2019 Drug Price Forecast, predicts a continued growth of pharmaceutical costs that far exceeds both inflation and wage growth.

Pharmaceutical costs are already a large share of most health organizations’ budgets, and this is unlikely to change.

There are a number of factors contributing to this trend — for one, specialty drug price inflation. Overall, the predicted total specialty inflation rate of 4.23% is similar to the general drug inflation rate of 4.57%. But this new price projection is important for health system leaders since prices of specialty drugs tend to outweigh prices for non-specialty medications. This inflation rate will likely result in the need for providers to increase their drug budgets in the coming year.

Drug shortages, which of course compromise patient care, will likely contribute both directly and indirectly to overall higher costs.
 

Twitter: @JELagasse

Email the writer: jeff.lagasse@himssmedia.com

News Feed

Category: News Tags: account, approvals, Cancer, Drug, Drugs, Says, Tufts, U.S.
Post navigation
← The new saggy skin fix that knocked 10 years off this woman’s face Why Sports Improves Mental Health: 5 Facts in Favor of Training →
  • 5 categories of quality web content for you to explore when we cease daily publication
    Many of you have asked by email or on Twitter, “Where do we turn for help after you go away?” First, we’re not disappearing on January 1, 2019, and the […]
  • A quiet healthcare crisis in dentistry – Washington Examiner
    Few things are more concerning than kids without access to quality medical care. That’s especially true when the kids in question have special needs. Yet […]
  • Reflections on a 45-year career and 13 years leading HealthNewsReview.org
    Our home page 1st day 2006 In this, our final week of daily publishing as we wind down operations due to a loss of sufficient funding, I want to share […]
  • Macron to address the nation as France’s epidemic surges
    French President Emmanuel Macron has scheduled a televised address to the nation, a possible harbinger of tighter restrictions to combat surging […]
  • LifeBridge Health faces class-action lawsuit stemming from massive cyberbreach in 2016
    Law firm Murphy, Falcon & Murphy has filed a statewide class action lawsuit against Baltimore provider LifeBridge Health on behalf of more than […]
  • Instaflex Joint Support, 90 Count
    Instaflex Joint Support is a revolutionary joint health formula that has been scientifically formulated to help support joint comfort. Features an […]
Copyright 2018
Iconic One Theme | Powered by Wordpress